Symbols

NKTR

Nektar Therapeutics·NASDAQ

--(--)

NKTR fundamentals

NKTR Q4 2025 Earnings

Nektar Therapeutics (NKTR) released its earnings on Mar 12, 2026: revenue was 21.81M (YoY -25.25%), beat estimates; EPS was -1.78 (YoY -495.56%), beat estimates.

Revenue / YoY

21.81M

-25.25%

EPS / YoY

-1.78

-495.56%

Report date

Mar 12, 2026

NKTR Earnings Call Summary for Q4,2025

REZPEG Phase IIb Success: Showcased durability with 5x EASI-100 improvement and monthly/quarterly dosing, positioning as novel Treg-targeting biologic.
Market Leadership: $33B atopic dermatitis market with only 10% penetration; REZPEG Phase III to start June 2026, BLA in 2029.
Financial Strength: $400-460M cash by end-2026; 2026 R&D spend $200-250M for Phase III.
Alopecia Catalyst: 52-week data in April 2026; potential to match low-dose JAK efficacy with better safety profile.
Type 1 Diabetes Expansion: Phase II with TrialNet; C-peptide preservation data expected 2027.

Earnings

EPS

Revenue

Revenue & Expenses

NKTR has released its 2025 Q4 earnings report, with revenue of 21.81M, reflecting a YoY change of -25.25%, and net profit of -36.08M, showing a YoY change of -596.89%. The Sankey diagram below clearly presents NKTR's revenue sources and cost distribution.

Key Indicators

Nektar Therapeutics (NKTR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Nektar Therapeutics (NKTR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Nektar Therapeutics (NKTR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Nektar Therapeutics (NKTR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown